This is an interesting conclusion? I guess they talked to the people who were in the various studies for Byetta and came out with these findings.
We have received feedback from the field that patients are receiving multiple Byetta [injection] pens per prescription," Piper Jaffray said. "These comments led us to analyze the number of pens/Byetta prescription. Contrary to current thinking that 1 prescription = 1 pen, our analysis of IMS data indicates 1 prescription = 1.3 pens (i.e., 30% more dollars)."
I hope it's not because Byetta isn't as effective as the regular insulin drugs. Maybe it is because the people in the study are buying an extra one to keep at home and one to take with them when they travel or go to work. If that were the case it would be similar to an asthma inhaler. Should be a nice drug once it gets to market. This analysts agrees:
Piper Jaffray continues to believe that Byetta "could be the next biotech blockbuster."
No comments:
Post a Comment